UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline

In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Ultragenyx Pharmaceutical (NASDAQ: RARE ) with an Overweight rating and $81.00 price target. In the report, Morgan Stanley noted, “Ultragenyx is an orphan disease focused co. that has in-licensed a series of interesting early/mid stage drugs. The